Endpoints News 生物医药· ENDPOINTS·· 10 天前AI 评分35
PepGen 的寡核苷酸疗法在 DM1 中期试验中取得积极信号
PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sag
AI 导读
PepGen 的寡核苷酸疗法 PGN-EDODM1 在 DM1 的中期试验中显示出早期积极信号。Ionis 和 ImmunityBio 的股票下跌。
正文
Plus news about Coherus Oncology, JW Therapeutics and PsiThera.
PepGen’s positive mid-stage results in DM1: PepGen said its oligonucleotide therapy PGN-EDODM1 showed positive early signals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news